RxDoctor Payments DataLook up a doctor →

Jacqueline Rosenthal, MD

Neurology · Atlanta, GANPI 1174759039

Payments from drug & device makers

$660,155in general payments, 2019–2025

Across 619 payments — averaging $1066.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$422K
  • EMD Serono, Inc.$99K
  • TG Therapeutics, Inc.$49K
  • Amgen$38K
  • Sanofi$19K
  • Biogen$10K
  • plus $23K from 17 others
$2,660in research payments, 2019–2025

Across 1 payment — averaging $2660.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$3K

What the payments were for

  • Consulting fees$85,03935%
  • Speaking & faculty fees$124,53352%
  • Grants$2,0001%
  • Travel & lodging$4,5902%
  • Food & beverage$20,2168%
  • Education$2730%
  • Charitable contribution$4,0002%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$660,155 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$11,214
Medicare patients
81
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MavencladCladribine11$976,822
Kesimpta PenOfatumumab102$923,020
AubagioTeriflunomide26$235,755
ZeposiaOzanimod Hydrochloride16$188,934
GilenyaFingolimod Hcl14$144,464
CopaxoneGlatiramer Acetate14$92,122
Teriflunomide65$79,073
Glatiramer Acetate25$55,532
AmpyraDalfampridine11$46,867
Dalfampridine ErDalfampridine98$20,707
MyrbetriqMirabegron19$11,016
Baclofen345$10,139
FingolimodFingolimod Hcl20$7,995
Oxcarbazepine77$4,726
Gabapentin165$2,817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Mavenclad$99,252$976,82211 claims
SanofiAubagio$19,033$235,75526 claims
E.r. Squibb & Sons, L.L.C.Zeposia$71$188,93416 claims
NovartisGilenya$421,986$144,46414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 506 neurology providers in Georgia.

Other neurology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →